The FDA plans to hold a two-day meeting beginning tomorrow to discuss ways to improve its MedWatch system to monitor side effects of drugs the agency has approved. The meeting became more significant in the wake of the withdrawal of major drugs from the market because of associated heart risks, leading to criticism of the FDA's handling of their approval.

Full Story:

Related Summaries